Search Results

Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused on targeting GPCR heteromers in cancer, headquartered in Seoul, Korea, with an R&D facility in the SF Brian Kobilka , studying the dimerization of GPCRs. Dr. Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review.

Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

together to advance biology and therapeutics. 📚 Learn faster. 🤝 Connect deeper. 🔬 Drive discoveries Explore 200+ expert talks that bring GPCR discoveries to life From structural biology to therapeutics agonists and antagonists shape efficacy, signaling, and therapeutic potential. orthosteric drugs and uncover the power of allosteric modulators and kinetic insights to unlock new therapeutic Take the Next Step You're building the future of GPCR therapeutics.

technology for high-throughput screening of pharmacological compound libraries to identify potential therapeutic "Ana Lilia Moreno Salinas (2), Arturo Mancini (1), Raida Jallouli (2), Richard Leduc (2) (1)Domain Therapeutics Laurent Sabbagh on the web Domain Therapeutics Characterizing hADGRE5/CD97 Activation and Signaling: Domain Therapeutics North America Inc., Montreal, Quebec, Canada 3. ), with a particular focus on the adhesion GPCRs (aGPCRs) family.

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program ADGRG1/GPR56 regulates survival of terminally differentiated CD8+ T cells Cheng-Chih Hsiao Adhesion GPCR Attendees About Douglas Tilley "Research in the Tilley laboratory focuses primarily upon aspects of GPCR in the regulation of physiologic/pathologic function in the heart in an effort to uncover novel therapeutic directions for HF, including adhesion GPCRs (AGPCRs).

This made me pursue my higher education in the field of adhesion GPCRs. Emmanouil Kyrloglou on the web Adhesion GPCR Consortium LinkedIn A single cell GPCR map of thermogenic , located within the GPCR autoproteolysis inducing (GAIN) domain. graduate student, he worked in the EuGEF Research Group to identify novel prognostic biomarkers and therapeutic Clearly, a new, less toxic therapeutic is needed.

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program GPCR Community Presentation Breaking Barriers: My Journey from Mexico to the Heart of the Dr. GPCR Ecosystem and beyond About Monserrat Avila Zozaya "My doctoral research was focused on investigating My research focuses on understanding the molecular mechanisms of adhesion GPCRs (aGPCRs) in lymphatic GPCR < Previous Session Next Session >

My research focuses on understanding the molecular mechanisms of adhesion GPCRs (aGPCRs) in lymphatic GPCR Adhesion GPCR BAI1/ADGRB1 can block IGF1R-mediated growth signalling, increase radiosensitivity understanding the molecular basis for human tumor development and how to use this knowledge to devise new therapeutics Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic Like many other aGPCRs, ADGRG6 undergoes autoproteolysis at the GPCR-autoproteolysis site (GPS) enclosed

Your One-Stop-Shop for GPCR Drug Discovery and Development Researchers developing GPCR-targeted therapeutics solutions including cell-based assays for basic research through therapeutic discovery and development Principle of Eurofins DiscoverX Cell-based Assays Whether you are developing small-molecule or biologic therapeutic Explore GLP-1 Product Solutions to Support Obesity/Diabetes See GLP-1 Solutions Accelerating Obesity Therapeutics Eurofins Discovery GPCR services provides the industry's most extensive collection of validated GPCR

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program Activation: Direct Communication of Extracellular Region with Transmembrane Domain in a Holo-Adhesion GPCR point mutant knock-in mouse, H381S Frank Kwarcinski Tethered Peptide Activation Mechanism of Adhesion GPCRs Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA; Division of Molecular Therapeutics, New York State

into industry, and his role leading and shaping multidisciplinary teams for screening and innovative therapeutics How advanced assay design is essential for translating cell-based GPCR signals to therapeutic outcomes Martin Marro leads the Cell Pharmacology group in the Diabetes, Obesity and Complications Therapeutic Marro’s career advanced through roles at Novartis and Tectonic Therapeutic, contributing to projects across key therapeutic areas—spanning metabolic, cardiovascular, and gastrointestinal diseases.

Subscribe to the Adhesion GPCR Workshop 2024 newsletter. Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Register AGPCR Newsletter Adhesion GPCR Consortium Newsletter - May 2024 Welcome to the 4th official Adhesion GPCR Consortium newsletter GPCR News Register for the Adhesion GPCR 2024 Learn more about the Adhesion GPCR workshop 2024 Up About the event Learn more about the Adhesion GPCR workshop 2024 and its preliminary program.

GPCR Webinar Series was created to accelerate GPCR research by connecting scientists directly with leaders Each session explores mechanistic models, translational challenges, and real-world therapeutic implications GPCR platform. Do I need prior knowledge of GPCR pharmacology? Are these GPCR webinars free? Yes. All live GPCR webinars are free to attend. GPCR University.

Home Registration Full Agenda Venue Travel Tips Sponsors Special Issue on Adhesion GPCRs CINVESTAV, Mexico City, Mexico October 23-25 Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October Read More 12:00 PM Coffee Break with lights snacks Read More 12:30 PM State of the Art Talk Adhesion GPCR GPCR Community Presentation Monserrat Avila Zozaya Read More 11:30 AM Session VIII Physiological and map of thermogenic fat Gavin Zhang NovoiSMART - A new platform for GPCR antibody drug discovery

Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights concentrations, her work highlights why receptor localization and protein complex assembly matter for therapeutic localized signaling events, how these mechanisms are hijacked in disease, and how they can be leveraged for therapeutic GPCR Premium . GPCR Podcast? Leave a Review.

Explore GPCR lipid rafts, bitter taste receptor pharmacology, and data integration in this expert interview therapeutic landscape of bitter taste receptors, and the importance of data-driven resources. GPCR Premium. efficacy and diagnostic innovation What the functional diversity of bitter taste receptors means for novel therapeutic GPCR Podcast? Leave a Review.

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics , a company using machine learning to unlock new GPCR-targeted therapies. research career The inside story behind founding Blue Therapeutics and targeting supraspinal pain pathway Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics led Ajay Yekkirala to reshape the future of GPCR-targeted medicine. Enjoying the Dr. GPCR Podcast?

Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential signaling and drug discovery Symposium & Workshop - Brazil NEW April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology - UK Jobs NEW Open Postdoctoral position - Stanford University Structural Biologist - Confo Therapeutics Pharmacologist - Schrödinger Scientist - Biology - Superluminal Medicines Scientist I Cell Biology - Tectonic Therapeutic

particular, drives tumor growth via effects on GBM stem cell self-renewal and metabolism, but also has a therapeutically their therapeutic targeting." Javitch1,2 1Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University , New York, NY 10032; 2Division of Molecular Therapeutics, New York State Psychiatric Institute, New GPCR < Previous Session Next Session >

I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics was the 6th employee and today we are more than 60 :) I have fun every day, and I love working with GPCRs Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review.

He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks

GPCR Ecosystem. important families of therapeutic targets in the pharmaceutical industry. therapeutics. GPCR. accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic

From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics Falling in Love with GPCRs GPCR pharmacology captured his scientific curiosity. as therapeutic targets. He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general GPCR Podcast? Leave a Review.

Discover how GPR65 reshapes our understanding of GPCR signaling and its role in cancer, with Dr. GPCR podcast. << Back to podcast list Strategic Partner(s) Signals, pH, and Discovery : Cracking GPCR Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic micro environments could unlock new therapeutic strategies GPCR Podcast? Leave a Review.

build a productive, independent scientific research career in adhesion G protein-coupled receptor (aGPCR a basis for understanding aGPCR biology in the nervous system. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks

Discover the essence of GPCR Retreat, an international GPCR Event that empowers the GPCR field. Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat The GPCR Retreat focuses on advances in our understanding of how GPCRs operate in cell communication. Registration to the GPCR Retreat is capped at 200 participants to promote an intimate environment. in the Ottawa 2017 edition, to showcase the breadth of diversity in GPCR trainee communities.

company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics , particularly GPCR antagonists. of GPCR function to better target receptors. GPCR Member ResearchGate Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review.

< Back Your GPCR Order Has Arrived! Ligands as Therapeutic Drugs starting March 20 – April 10, 2025 (Thursdays, 10:00 AM–12:00 PM EST). biotechs public Aikium's AI-Driven mRNA Engine Looks to Address Undruggable Disordered Proteins Tectonic Therapeutic and drug discovery Symposium & Workshop NEW April 2 - 3, 2025 | New therapeutic modalities: Transforming Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic Senior

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program Kordon Deorphanization Of The Adhesion GPCRs GPR110 and GPR116 Tingzhen Shen Self-Cleavage of GPR110 Activity In The G12/13 Pathway Júlia Rosell Endocytic Cues Determine the Signaling Profile of Adhesion GPCR University of Copenhagen, Copenhagen, Denmark. (2) Department of Psychiatry and Molecular Pharmacology and Therapeutics Columbia University Vagelos College of Physicians and Surgeons, New York, USA; Division of Molecular Therapeutics

Rosie Dawaliby "I’m an expert in early-stage drug discovery, targeting membrane proteins, especially GPCR I have developed my expertise in the field of pharmacology and biochemistry of GPCR and the crucial role In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases GPCR Ecosystem G.CLIPS Biotech on the web Website LinkedIn Enjoying the Dr. GPCR Podcast?